Evidence map›Paper›PMID 38914824›Full record

ArticleLab animal2024

Model matchmaking via the Solve-RD Rare Disease Models & Mechanisms Network (RDMM-Europe).

Kornelia Ellwanger, Julie A Brill, Elke de Boer, Stephanie Efthymiou, Ype Elgersma, Marynelle Icmat, François Lecoquierre, Amanda G Lobato, Manuela Morleo, Michela Ori and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lab animal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Functional assays inGenome research · 2025
    Review
  3. Global partnerships in rare disease research.Disease models & mechanisms · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Kornelia EllwangerInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany. kornelia.ellwanger@med.uni-tuebingen.de.ORCID 0000-0003-4845-5795
Julie A BrillThe Hospital for Sick Children, Toronto, Ontario, Canada.ORCID 0000-0002-5925-9901
Elke de BoerDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID 0000-0002-7022-577X
Stephanie EfthymiouDepartment of Neuromuscular Disorders, Queen Square Institute of Neurology, University College London, London, UK.
Ype ElgersmaDepartment of Clinical Genetics, Erasmus Medical Centre, Rotterdam, the Netherlands.
Marynelle IcmatThe Hospital for Sick Children, Toronto, Ontario, Canada.
François LecoquierreNormandie Univ, UNIROUEN, Inserm U1245, CHU Rouen, Department of Genetics, FHU G4 Génomique, Rouen, France.
Amanda G LobatoDepartment of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID 0000-0002-4218-7817
Manuela MorleoTelethon Institute of Genetics and Medicine (TIGEM), Pozzuoli (Na), Italy.
Michela OriDepartment of Biology, University of Pisa, Pisa, Italy.ORCID 0000-0002-6777-0208
Ashleigh E SchafferDepartment of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH, USA.ORCID 0000-0002-1164-697X
Antonio VitobelloINSERM-Université de Bourgogne UMR1231 GAD «Génétique Des Anomalies du Développement», FHU-TRANSLAD, UFR Des Sciences de Santé, Dijon, France.
Sara WellsThe Mary Lyon Centre at MRC Harwell, Harwell Science Campus, Oxon, UK.
Binnaz YalcinInserm Unit 1231, University of Bourgogne Franche-Comté, Dijon, France.ORCID 0000-0002-1924-6807
R Grace ZhaiDepartment of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID 0000-0002-7599-1430
Marc SturmInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.ORCID 0000-0002-6552-8362
Birte ZurekInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Holm GraessnerInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Eva Bermejo-SánchezInstitute of Rare Diseases Research (IIER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Teresinha EvangelistaSorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, Paris, France.ORCID 0000-0002-1329-9131
Nicoline HoogerbruggeDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.
Vincenzo NigroTelethon Institute of Genetics and Medicine (TIGEM), Pozzuoli (Na), Italy.
Rebecca SchüleDepartment of Neurodegeneration, Hertie Institute for Clinical Brain Research (HIH), University of Tübingen, Tübingen, Germany.
Alain VerloesDepartment of Genetics, Assistance Publique-Hôpitaux de Paris - Université de Paris, Robert DEBRE University Hospital, Paris, France.
Han BrunnerDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.
Philippe M CampeauDepartment of Pediatrics, CHU Sainte-Justine and University of Montreal, Montreal, Quebec, Canada.ORCID 0000-0001-9713-7107
Paul LaskoDepartment of Biology, McGill University, Montreal, Quebec, Canada.
Olaf RiessInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany. olaf.riess@med.uni-tuebingen.de.

Funding

Disease Mechanisms of Pontocerebellar Hypoplasia Type 10R01NS123524 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI SCHAFFER, ASHLEIGH E · 2021 to 2025
$2.6M
NINDS NIH HHS R01 NS123524
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Disease Models, AnimalRare DiseasesAnimalsEuropeHumans

Identifiers

PMID38914824
PMCPMC11216991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.